Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance

pharmafile | September 13, 2017 | News story | Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis 

At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx (secukinumab) evidencing its long term skin clearance benefits and safety profile in the treatment of psoriasis.

The trial measured the drug’s efficacy using the Psoriasis Are and Severity Index (PASI), where a response of 75, 90 or 100 was seen as a success regarding efficacy, with 100 representing full skin clearance. In the period ranging from 52 weeks of treatment to a full five years, Consentyx produced consistent response rates; at 52 weeks, 89% of patients achieved a PASI score of 75, while 69% achieved a score of 90, and this was maintained until the end of the five years, producing rates of 89% and 66% respectively.

Furthermore, by the end of the first year, 44% of patients achieved complete skin clearance, which was maintained at year five with a rate of 41%.

Advertisement

Consentyx is the first and only fully-human IL-17A inhibitor approved in the treatment of psoriasis, plaque psoriasis and ankylosing spondylitis. Administered once a month via an auto injector, the drug has been used to treat over 100,000 patients over 10 years.

“The five-year data reinforce Cosentyx as an important treatment option for those people living with psoriasis who aspire for skin clearance that can last,” said Vas Narasimhan, Global Head of Drug Development and Chief Medical Officer at Novartis.

Matt Fellows

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

The Gateway to Local Adoption Series

Latest content